ReviewFrontiers in endocrinology2015
The potential use of DNA methylation biomarkers to identify risk and progression of type 2 diabetes.
Review in Frontiers in endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- The role of epigenetic signatures in type 2 diabetes: therapeutic advances and lifestyle interventions.Acta diabetologica · 2026Review
- Pharmaco-Epigenetics and Epigenetic Drugs in Type 2 Diabetes: Can Epigenetics Predict Drug Efficiency?Biomedicines · 2025Review
- Review of Associations of Diabetes and Insulin Resistance With Brain Health in Three Harmonised Cohort Studies of Ageing and Dementia.Diabetes/metabolism research and reviews · 2025Review
- Multi-tissue epigenetic analysis identifies distinct associations underlying insulin resistance and Alzheimer's disease at CPT1A locus.Clinical epigenetics · 2023Article
- The Transcription FactorCells · 2023Review
- The transcriptomic and epigenetic alterations in type 2 diabetes mellitus patients of Chinese Tibetan and Han populations.Frontiers in endocrinology · 2023Article
- DNA Methylation in Gestational Diabetes and its Predictive Value for Postpartum Glucose Disturbances.The Journal of clinical endocrinology and metabolism · 2022Observational
- Predicting High Blood Pressure Using DNA Methylome-Based Machine Learning Models.Biomedicines · 2022Article
- Mini-review: Mitochondrial DNA methylation in type 2 diabetes and obesity.Frontiers in endocrinology · 2022Review
- DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?International journal of molecular sciences · 2021Review
- Increased PARylation impacts the DNA methylation process in type 2 diabetes mellitus.Clinical epigenetics · 2021Article
- Epigenetics of Hepatic Insulin Resistance.Frontiers in endocrinology · 2021Review
- A role of glycation and methylation for SARS-CoV-2 infection in diabetes?Medical hypotheses · 2020Article
- Hypermethylation in Calca Promoter Inhibited ASC Osteogenic Differentiation in Rats with Type 2 Diabetic Mellitus.Stem cells international · 2020Article
- Altered Genome-Wide DNA Methylation in Peripheral Blood of South African Women with Gestational Diabetes Mellitus.International journal of molecular sciences · 2019Article
- Nutritional Factors, DNA Methylation, and Risk of Type 2 Diabetes and Obesity: Perspectives and Challenges.International journal of molecular sciences · 2019Review
- Epigenetics in Human Obesity and Type 2 Diabetes.Cell metabolism · 2019Review
- Global and gene-specific DNA methylation in adult type 2 diabetic individuals: a protocol for a systematic review.Systematic reviews · 2018Article
- Reduced mRNA and Protein Expression Levels of Tet Methylcytosine Dioxygenase 3 in Endothelial Progenitor Cells of Patients of Type 2 Diabetes With Peripheral Artery Disease.Frontiers in immunology · 2018Article
- DNA methylation and its role in the pathogenesis of diabetes.Pediatric diabetes · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2D) is a slowly progressive disease that can be postponed or even avoided through lifestyle changes. Recent data demonstrate highly significant correlations between DNA methylation and the most important risk factors of T2D, including age and body mass index, in blood and human tissues relevant to insulin resistance and T2D. Also, T2D patients and individuals with increased risk of the disease display differential DNA methylation profiles and plasticity compared to controls. Accordingly, the novel clues to DNA methylation fingerprints in blood and tissues with deteriorated metabolic capacity indicate that blood-borne epigenetic biomarkers of T2D progression might become a reality. This Review will address the most recent associations between DNA methylation and diabetes-related traits in human tissues and blood. The overall focus is on the potential of future epigenome-wide studies, carried out across tissues and populations with correlations to pre-diabetes and T2D risk factors, to build up a library of epigenetic markers of risk and early progression of T2D. These markers may, tentatively in combination with other predictors of T2D development, increase the possibility of individual-based lifestyle prevention of T2D and associated metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.